Green Myke R, Chowdhary Sajeel, Lombardi Kristina M, Chalmers Lisa M, Chamberlain Marc
University of South Florida, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, Florida 33611, USA.
Expert Rev Neurother. 2006 May;6(5):635-52. doi: 10.1586/14737175.6.5.635.
Primary CNS non-Hodgkin lymphoma (PCNSL) has been shown to be increasing in incidence. This appears to be a consequence of the increasing population of those older than 65 years of age in whom PCNSL occurs most often. PCNSL often has a favorable response to treatment and aggressive management may result in extended survival and, in a proportion of patients less than 65 years of age, cure. The majority of neuro-oncologist's advocate utilizing high-dose methotrexate (HD-MTX) as a platform for the chemotherapy treatment of these neoplasms. In this review, the literature regarding HDHMTX as a treatment for PCNSL is summarized as are the pharmacological principles of HD-MTX.
原发性中枢神经系统非霍奇金淋巴瘤（PCNSL）的发病率已呈上升趋势。这似乎是65岁以上人群数量增加的结果，PCNSL在这一年龄段人群中最为常见。PCNSL通常对治疗反应良好，积极的治疗管理可能会延长生存期，对于一部分年龄小于65岁的患者，甚至可能治愈。大多数神经肿瘤学家主张将大剂量甲氨蝶呤（HD-MTX）作为这些肿瘤化疗治疗的基础用药。在本综述中，总结了有关HD-MTX治疗PCNSL的文献以及HD-MTX的药理学原理。
